Pending FDA approval, trials to begin on ALung's artificial lung
ALung Technologies Inc. spent four years working on technology to aid a patient's breathing before deciding to change gears in 2005 and focus development on an artificial lung device.
The switch might have been a momentum-killer, the kind that sends startup tech companies to an early grave.
Yet investors kept ALung afloat for a dozen years with $40 million because they believed in the company, officials said.
“The idea of this treatment has always captured the imagination,” Nicholas Kuhn, ALung's chief business officer, said at the company's South Side offices. “There was always investor support.”
ALung's development has been an exercise in patience, which is not uncommon in medical device development. It was founded in 1997 to hold licenses for technology developed by University of Pittsburgh researchers but didn't have employees or begin operations until 2001, Kuhn said.
Starting in 2001, ALung pursued an intravenous catheter that would filter carbon dioxide and add oxygen directly to a patient's bloodstream. They found they couldn't make the device small enough to easily insert into a vena cava, a vein that carries oxygen-depleted blood to the heart.
“We realized we needed to take a different approach,” Kuhn said. “It wasn't an easy decision.”
The device they settled on — the Hemolung RAS — sits outside the body and performs the same task in a process analogous to a kidney dialysis machine. ALung started selling it in Europe this year and hopes to gain approval for U.S. sales by 2017.
The target date for U.S. sales could drag out, CEO Pete DeComo said.
“If there's anything that's true today, it's the cliche that everything is taking longer and costing more,” said DeComo, who joined ALung in 2008 after selling a company he founded, Renal Solutions, for $190 million.
ALung officials expected to meet with the Food and Drug Administration this month. It needs the agency's OK to begin a three-year clinical study of the Hemolung and could start trials next year if the FDA approves its study design, DeComo said.
Gaining FDA approval will require more money from investors. DeComo last year told the Tribune-Review that ALung likely would need $25 million for clinical trials.
This month, he declined to comment, citing Securities and Exchange Commission rules that prevent companies from discussing fundraising efforts while talking with investors.
In the meantime, ALung is working to expand sales across Europe.
“Patients in Europe benefit from new medical technology four to five years faster” than in the United States, DeComo said.
Sales this year “will be modest, most likely under $1 million,” he said. An expanded commercial launch will begin in 2014, enabling revenue to “accelerate and grow rapidly.”
If ALung's early success builds, the potential market for the Hemolung is huge. DeComo said 2.5 million Americans each year experience acute cardiorespiratory exacerbations, or trouble breathing, because of chronic obstructive pulmonary disease and other lung diseases.
The Hemolung is designed for patients who have trouble breathing or to supplement a mechanical ventilator.
Many patients with reduced lung function are placed on ventilators because no other option exists. Ventilators can cause lung infections, and often a patient's lungs become dependent on the machine. ALung's device could help patients who still have some lung function.
About 1 million people worldwide use ventilators, DeComo said. The potential market size could be $6.3 billion a year, including $2.7 billion in the United States.
The 40-employee company leases space in a renovated factory that includes room for assembly of the Hemolung. That's unique among most startup medical device companies, which find it more cost-effective to outsource manufacturing, DeComo said.
ALung maintains control so that it can ensure quality, he said. The company produces about 10 Hemolungs a month.
Alex Nixon is a staff writer for Trib Total Media. He can be reached at 412-320-7928 or email@example.com.
Add Alex Nixon to your Google+ circles.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Stocks end 5-day slide on strong Ford, UPS earnings
- Consol Energy, Range Resources report 2Q losses, plan deeper cuts
- U.S. Steel joins major producers in new dumping complaint
- Muni bond funds stressed
- Ambridge’s PittMoss takes off with help from TV show, Mt. Lebanon native Cuban
- Leisure, hospitality lead Pittsburgh area job gains
- Bayer sets sights beyond aspirin
- Plummeting natural gas prices slash revenue of Marcellus shale producers
- Analysts fear momentum in housing market won’t last
- Chronic job-seekers giving up the hunt
- Israel’s Teva drops bid for Mylan, buys Allergan for $40.5B